Medpace Holdings, Inc. (MEDP)

In the past six months, Medpace Holdings, Inc. stock has trended down. Key events include strong Q4 2025 financial results with increased revenue and net income, but the market responded negatively due to elevated cancellations and margin pressure. Analyst sentiment has been mixed, with some upgrades and insider selling by President Jesse Geiger. Broader market trends, including U.S.-Iran conflict fears and sector pressures, have also influenced the stock performance, and the company is scheduled to report its first-quarter 2026 financial results on April 22, 2026.

Medpace Holdings, Inc. exhibits distinct seasonal tendencies in its stock performance based on historical data over 10 years. July has been the strongest month, while February tends to be the weakest. The company has an average annual return of 31.13% with a monthly win rate of 58.1%, and the seasonal pattern has a consistency score of 62.2, which is considered "Good".

Medpace Holdings, Inc. is a global, scientifically-driven, full-service clinical contract research organization (CRO) that provides drug and medical device development services to the biotechnology, pharmaceutical, and medical device industries. The company offers outsourced clinical development services, supporting the entire clinical development process from Phase I to Phase IV, specializing in various therapeutic areas such as oncology, cardiology, and central nervous system.

Medpace Holdings, Inc. is headquartered in Cincinnati, Ohio, and has a significant global presence with approximately 6,200 employees across 46 countries as of December 31, 2025. The company operates primarily in the U.S., with additional presence in Europe, Asia, South America, Africa, and Australia, including regional offices and clinical sites across North America, Europe, Asia, and Latin America.

Medpace's brand reputation has faced scrutiny, particularly concerning its business awards and operational efficiency. Shares fell after new business awards declined in Q1 2025, leading to negative sentiment from sponsors. In February 2026, Medpace Holdings came under investigation after a "Book-to-Bill Miss" exposed a "Cancellation Surge and Pipeline Fragility," with the CEO acknowledging elevated cancellations in Q4 2025 impacting the metabolic therapeutic area.

Medpace Holdings, Inc. has a diverse ownership structure, with institutional investors holding a dominant stake of approximately 77.98% as of March 31, 2025. Major institutional shareholders include BlackRock, Inc. and Vanguard Group Inc. Dr. August Troendle, the founder and CEO, is a major individual shareholder, holding between 19% and 21% of the company's stock, and Medpace Limited Partnership is also a significant insider owner.